Epcoritamab
Epcoritamab
Epcoritamab (pronunciation: ep-co-ri-ta-mab) is a bispecific antibody designed for the treatment of B-cell malignancies. It is currently under investigation in clinical trials.
Etymology
The name "Epcoritamab" follows the World Health Organization's guidelines for the naming of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the infix "-rit-" suggests that it targets the immune system.
Mechanism of Action
Epcoritamab works by binding to two different proteins: CD3 on T-cells and CD20 on B-cells. This dual binding allows T-cells to directly kill the B-cells, which are often cancerous in B-cell malignancies.
Clinical Trials
Epcoritamab is currently being tested in several clinical trials for its effectiveness against various B-cell malignancies, including Non-Hodgkin lymphoma and Chronic lymphocytic leukemia.
Related Terms
- Monoclonal antibody
- B-cell
- CD3
- CD20
- Clinical trial
- Non-Hodgkin lymphoma
- Chronic lymphocytic leukemia
External links
- Medical encyclopedia article on Epcoritamab
- Wikipedia's article - Epcoritamab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski